# Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

> **NCT00726180** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab (Herceptin®)

## Key facts

- **NCT ID:** NCT00726180
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to low enrollment
- **Last updated:** 2013-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726180, "Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00726180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*